Customized Rabbit Models of Retinoblastoma

Inquiry

The development of novel therapeutics or drug delivery systems requires appropriate model support. As one of the global leaders in ocular disease models, Ace Therapeutics offers a variety of ocular disease models to meet your needs. Here, we developed a rabbit model of retinoblastoma induced by subretinal injection of WERI human retinoblastoma cells under hyperimmune conditions. This model is similar to human retinoblastoma and can help you test against new treatments for this disease.

Rabbit Models of Retinoblastoma

What Is Retinoblastoma?

Retinoblastoma is the most common primary intraocular http://ophthalmology.141154.cd-web.org/wp-admin/post-new.php?post_type=pagetumor of childhood and curable cancer. It is caused by two allelic mutations in the RB1 tumor suppressor gene and is a heritable/non-heritable eye disease. According to incomplete statistics, non-hereditary retinoblastoma accounts for the majority (60%) of cases where the RB1 allele is locally mutated in the affected retina. Hereditary retinoblastoma (40%) is associated with germline predisposing variants in RB1 followed by somatic inactivation of other alleles. Clinically, chemotherapy is the standard of care for this disease, but it has unavoidable toxicity. Therefore, there is a need to discover new therapies that selectively target tumors while sparing the normal retina to improve therapeutic outcomes. There is an urgent need for suitable animal models to meet this need.

Fig. 1. Development of retinoblastoma. (Kaewkhaw R, et al., 2020)

Service Overview

The rabbit's large eyes make it an ideal model for a locally targeted drug delivery platform for retinoblastoma. Thanks to the in-depth understanding and research of retinoblastoma, Ace Therapeutics has developed a rabbit retinoblastoma model for our clients to study new treatments for this disease and to test various possible routes of administration, such as transscleral locally targeted drug delivery therapy.

Explore Ace Therapeutics' Rabbit Models of Uveitis

Ace Therapeutics' rabbit model of retinoblastoma was achieved by intramuscular injection of the immunosuppressant cyclosporine A (CsA) combined with subretinal injection of WERI human retinoblastoma cells. This was followed up for up to 8 weeks. CsA administration avoids spontaneous tumor regression, ensures the reliability of the entire research process, and greatly improves model success chances.

Model Characteristics: One week after treatment of retinoblastoma cells in immunocompromised rabbits, a prominent intraocular tumor was observed on fundoscopy, with vascularization beginning at week five and continuing until the end. The histopathological features of this model resemble those of human retinoblastoma patients. It can be used to evaluate novel therapies for transcellular drug delivery.

In order to monitor the specific conditions of New Zealand white rabbits injected with WERI human retinoblastoma cells to assess the presence and extent of tumors in the eyes, Ace Therapeutics uses the following indicators as evaluation endpoints, including but not limited to:

Ophthalmology and ultrasonography.
Histopathological examination.
Optical microscopy analysis.

It is worth mentioning that we also provide genetically engineered mouse models of retinoblastoma to help you discover and study candidate pathways and therapies for molecularly targeted therapy of human retinoblastoma. Please click on the link to visit.

Ace Therapeutics aims to provide global customers with a powerful experimental tool to evaluate the effectiveness of potential locally targeted therapies against retinoblastoma. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Kaewkhaw R, Rojanaporn D. Retinoblastoma: Etiology, Modeling, and Treatment. Cancers (Basel). 2020, 12(8):2304.
Kang SJ, Grossniklaus HE. Rabbit model of retinoblastoma. J Biomed Biotechnol. 2011, 2011:394730.

For Research Use Only.

Get in Touch